Fergus Fleming, Chief Technology Officer Fergus Fleming has served as Renalytix’s Chief Technical Officer since its inception. Fergus has over 30 years’ experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific, Trinity Biotech plc, and EKF Diagnostics. Fergus has extensive experience in the design and manufacture in vitro diagnostics instruments and reagents. 

Dr. Sharon Stapleton PhD, Director of Scientific and Clinical Research and Development. Sharon has over 15 years’ experience working with both early-stage start-ups and global diagnostics companies, including leadership positions with EKF Diagnostics, OncoMark (acquired by Cepheid Inc.) and Trinity Biotech. She is an expert in the design and development of immunoassays and has extensive experience managing multi-site projects including clinical studies, new product introduction and regulatory submissions. Dr Stapleton has a PhD in Applied Biochemistry from Dublin City University, Ireland.

Dr Katherine Edwards, Research and Development Scientist, Junior Researcher. Currently responsible for design, execution and reporting of development and validation studies for novel biomarkers in CKD.  Previously, Katherine was a product engineering scientist for Trinity Biotech plc. and was involved with new product transfer, validation of new products, clinical studies and regulatory submissions to the FDA and WHO, as well as, for CE marking.  Katherine’s PhD focused on exploring new regulators of innate immune signalling pathways with a particular focus on inflammasomes. 

Dr. Steven G. Coca, Nephrologist, is a Professor of Medicine and the Associate Chair for Clinical and Translational Research for the Department of Medicine at the Icahn School of Medicine at Mount Sinai. His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and chronic kidney disease. Dr. Coca has been an active investigator in several large NIH-funded consortia (TRIBE-AKI, ASSESS-AKI, CKD Biocon, KPMP). He is a co-founder of Renalytix. 

Dr. Girish N. Nadkarni, Nephrologist, is the Fishberg Professor in Medicine at the Icahn School of Medicine at Mount Sinai, Chief of the Division of Data Driven and Digital Medicine (D3M) and Director of the Charles Bronfman Institute of Personalized Medicine. Dr. Nadkarni has authored 300 peer-reviewed scientific publications. He is the principal investigator for several NIH funded R01/U01 grants. Dr. Nadkarni is also the scientific co-founder of several investor-backed companies. 

Prof. Dr. Peter GM Mol, professor of drug regulatory science, University Medical Center Groningen, and senior clinical assessor at the CBG-MEB

Dr. Marjon (A.M.G.) Pasmooij, head of the science department, CBG-MEB

Dr. Viktoriia Starokozhko, clinical assessor, CBG-MEB

Lysbeth Bakker, PhD (-candidate)

Renkse Grupstra, PhD-candidate

Maria F. Gomez – Professor of Physiology at the Department of Clinical Sciences, Director of Lund University Diabetes Centre (http://www.ludc.lu.se) and Honorary Skou Professor at the Faculty of Health, Aarhus University, Denmark. After medical school, she completed her Ph.D. in physiology (Lund University; 1998) and post-doctoral studies in Pharmacology (University of Vermont; 2001). She has published ~136 papers and supervised 11 PhD theses, 13 post-docs and >30 students. She’s coordinator of IMI project BEAt-DKD (https://www.beat-dkd.eu/) and vice-coordinator of PRIME-CKD. 

Anders Christensen – Professor of Nephrology at the Department of Clinical Sciences Malmo, Lund University and Head physician of Nephrology at Skåne University Hospital, Malmö, Sweden. After medical school he completed his PhD in clinical chemistry (Lund University 1993). Postdoc at Rockefeller University, MSKCC, New York. His research is focused on GFR-markers, chronic kidney disease, protein research and epidemiology. He has published 100 papers and supervised 7 PhD theses. He is program director for renal care in Sweden. 

Christopher Nilsson – Post doc at the Department of Clinical Sciences Malmo, Lund University. After graduating from medical school at Lund University in 2017, he completed his Ph.D. in internal medicine (Lund University; 2021) focusing on the relationship between ethnicity, blood pressure and renal function. He is currently undergoing his medical residency in Internal medicine and Nephrology at Skåne University Hospital, Malmo. 

Abrar Ahmad – Postdoc at the Department of Clinical Sciences Malmo, Lund University. After graduating from veterinary school at University of Agriculture Faisalabad, Pakistan, he completed his master’s degree in Molecular Medical Biology at Örebro University, Sweden in 2012 and his Ph.D. in medical sciences at Lund University in 2018. His Ph.D. project focused on the identification of genetic biomarkers for the risk prediction of recurrent venous thromboembolism. He has published ~17 papers in the fields of cancer, cardiovascular diseases, and diabetes. 

Jacqueline Postma – Jacqueline did her MSc in Biology (Utrecht University; 1995), a PhD in Environmental Sciences (Wageningen University; 2003), followed by post-doctoral studies in Plant Ecology (Lund University; 2007), after which she switched to her career at LUDC. She is project manager for the IMI project BEAt-DKD (https://www.beat-dkd.eu/), as she was previously for IMI-SUMMIT (2009-2015). Jacqueline will be supporting Maria Gomez in PRIME-CKD.

Prof. Gaetano La Manna, MD, PhD: 
-Professor of Nephrology at University of Bologna
-Director of Nephrology Division at IRCCS Azienda Ospedaliero-Universitaria di Bologna.
-Principal investigator for Alma Mater Studiorum University of Bologna and IRCCS Azienda Ospedaliero-Universitaria of Bologna.

Dr. Michele Provenzano, MD, PhD:
-Junior Assistant Professor
-Researcher at University of Bologna
-Sub-investigator for Alma Mater Studiorum University of Bologna and IRCCS Azienda Ospedaliero-Universitaria of Bologna.

Dr. Giorgia Comai, MD, PhD: 
-Head of Kidney Transplant Unit at IRCCS Azienda Ospedaliero-Universitaria di Bologna
-Sub-investigator for Alma Mater Studiorum University of Bologna and IRCCS Azienda Ospedaliero-Universitaria of Bologna.

Prof. Irene Capelli, MD, PhD:
-Associate Professor of Nephrology at University of Bologna
-Sub-investigator for Alma Mater Studiorum University of Bologna and IRCCS Azienda Ospedaliero-Universitaria of Bologna.

Dr. Lilio Hu, MD:
-PhD Student in Nephrology
-Sub-investigator for Alma Mater Studiorum University of Bologna and IRCCS Azienda Ospedaliero-Universitaria of Bologna.

Temp Text

Wenjun Ju: PhD in molecular Biology. Lead contact of PRIME-CKD WP2. Dr. Ju is a Research Scientist in Department of Internal Medicine and Computational Medicine and Bioinformatics at UMICH. She has extensive experience in investigation of pathological mechanisms of CKD and non-invasive molecular mechanism-based biomarkers for kidney precision medicine. In PRIME-CKD, her responsibilities include leading the validation of the pharmacodynamic biomarkers in clinical trials (WP2) and working closely with colleagues from WP1 on the clinical-analytical evaluation of the biomarkers.

Matthias Kretzler. MD. Dr. Kretzler is the Warner-Lambert/Park-Davis Professor of Medicine and Director MiKTMC at the University of Michigan. Dr. Kretzler is the co-lead of WP2. He is the PI of the Nephrotic Syndrome Research Network (NEPTUNE) and the Kidney Precision Medicine Project. He integrated a kidney-specific research focus with the unique bioinformatic environment at UMICH for successful implementation of precision medicine strategies of renal diseases, from bioinformatic data mining to successful completion of targeted therapies in Phase II trials. In PRIME-CKD, Dr. Kretzler will provide oversight into data integration.

Viji Nair PhD: Dr. Nair is the lead bioinformatician/computational biologist on the MiKTMC at University of Michigan. Her research focus is in identifying non-invasive biomarkers and therapeutic targets predicting disease progression in Diabetic Nephropathy and CKD in general. Dr. Nair leads the bioinformatic efforts in multi-omics data integration by adapting a wide variety of established and novel computational approaches. In PRIME-CKD, Dr.Nair works in WP2 focusing on the investigation of molecular mechanisms underlying the biomarkers of interest with treatment response. 

Emily Tanner:  received her Bachelor’s of Science from Michigan State University where she double majored in Genomics & Molecular Genetics and Microbiology with a specialization in Bioethics, Humanities, and Society. She joined MiKTMC in November 2017 and is now a Research Specialist. In PRIME-CKD, she is responsible for conducting biomarker measurements (WP2).

Kai-Uwe Eckardt (MD, Professor) is principal investigator of the GCKD study and full Professor at Charité, Berlin. He is a clinician scientist, qualified as physiologist and internist with a track record in both experimental and clinical research. His main research interests include the pathogenesis and progression of chronic kidney disease. Prof. Eckardt has also participated in large interventional trials in CKD patients and is since long actively involved in international efforts to optimise treatment strategies. 

Mario Schiffer (MD, Professor) is the director of the Medical Clinic 4 at the University Hospital Erlangen, Germany and member of the GCKD steering committee. He is a clinician scientist, qualified as nephrologist and internist with a track record of accomplishment in both experimental and clinical research. His main research interests are the identification of novel pathways in proteinuric human diseases like diabetes, glomerulonephritis and transplant glomerulopathy.

Prof. Schneider (Researcher)

Dr. Meiselbach (GCKD study coordinator)

Prof. Hiddo Lambers Heerspink will act as project coordinator. He is a clinical pharmacologist and trialist with ample expertise in clinical trial design, biomarkers, and personalized medicine.  He has a proven track record in the coordination of complex international research projects: he was co-leader of the IMI2 BEAt-DKD program and leads scientific steering committees of international trials such as the FIND-CKD and ALIGN trials. He is a renowned clinical trialist and was involved as principal investigator in the DAPA-CKD trial that led to the first drug registration for patients with CKD in two decades.

Jasper Stevens, PhD will act as Executive Director for the PRIME-CKD project. He has a background in biology, pharmacology, and pharmacometrics and is an expert on the development of non-linear Population Approach Pharmacokinetic and Pharmacodynamic models. 

Daphne Kuiper, PhD is an expert on implementation research and applied health research. She will support and guide efforts to guarantee successful clinical implementation of the results from the PRIME-CKD project.

Reinder Broekstra, PhD is an expert on ethical, legal, and social aspects (ELSA) of personalized medicine, in particular of applying innovative Information Communication Technologies (ICT). He is member of institutional, national, and international expert groups on ELSA of ICT and biomedical research. Additionally, he is affiliated with the Clinical Ethics and Law group of the University of Southampton/Oxford.

Ana Sauri Peris, PhD is an experienced project manager who works as a project manager at UMCG Research BV. She is involved in the post-award project management of this EU project as well as other consultancy UMCG internal projects. 

Luca De Nicola is Full Professor in Nephrology and Director of Nephrology Unit and Postgraduate School of Nephrology at University of Campania, Naples, Italy, since 2019. His clinical and research activity is mainly dedicated to management of cardiorenal complications in non-dialysis CKD patients. He is author of almost 300 papers published on peer-reviewed internationa journals (H index 47), and he is/has been national leader of several RCTs on nephroprotection in CKD.

Roberto Minutolo is Associate Professor in Nephrology at University of Campania, Naples, Italy, since 2001. His clinical and research activity is mainly dedicated to management of complications in non-dialysis CKD patients. He is responsible for the outpatient clinic activities at Nephrology Division of University of Campania. He is author of more than 200 papers peer-reviewed published on main nephrology journals (H index 45) and he is/has been Member of the Editorial Boards for several journals.

Professor Jonathan Barratt & Dr Chee Kay Cheung are clinician scientists who undertake bench to bedside research into the causes and treatment of kidney diseases that affect the fine filters (glomeruli) of the kidneys. They have a major interest in IgA nephropathy, the commonest cause of glomerular disease in the world. This disease mostly affects young adults and commonly causes kidney failure. We have an active clinical trial program running at the John Walls Renal Unit where we treat patients with glomerular disease and a large laboratory facility at the University of Leicester where we study different experimental models of kidney damage. 

Dr. Stijn Gremmen is Work Package Leader for WP6 in the PRIME-CKD consortium and as such involved in networking and communication of results.

Stijn is working as Program Manager at the Dutch Kidney Foundation and involved in funding of scientific research and development projects. Previously, he has worked on complex chemistry problems in industrial drug discovery projects at several contract research organizations (2004 – 2021). He holds a PhD in bioorganic chemistry (University of Amsterdam, 2002).